The epigenetic state of the cell of origin defines mechanisms of leukemogenesis: ACUTE MYELOID LEUKEMIA

• Published in: Leukemia 2025, Vol.39 (1), p.87-97
• Main Authors: Li, Zhiheng, Fierstein, Sara, Tanaka-Yano, Mayuri, Frenis, Katie, Chen, Chun-Chin, Wang, Dahai, Falchetti, Marcelo, Côté, Parker, Curran, Christina, Lu, Kate, Liu, Tianxin, Orkin, Stuart, Li, Hojun, Lummertz da Rocha, Edroaldo, Hu, Shaoyan, Zhu, Qian, Rowe, R. Grant
• Format: Article
• Language: English
• Subjects: 45/100; 631/67/71; 64/60; 692/699/67/1990/283/1897; Cancer Research; Critical Care Medicine; Hematology; Intensive; Internal Medicine; Medicine; Medicine & Public Health; Oncology
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/s41375-024-02428-y

Acute myeloid leukemia (AML) shows variable clinical outcome. The normal hematopoietic cell of origin impacts the clinical behavior of AML, with AML from hematopoietic stem cells (HSCs) prone to chemotherapy resistance in model systems. However, the mechanisms by which HSC programs are transmitted to AML are not known. Here, we introduce the leukemogenic MLL-AF9 translocation into defined human hematopoietic populations, finding that AML from HSCs is enriched for leukemic stem cells (LSCs) compared to AML from progenitors. By epigenetic profiling, we identify a putative inherited program from the normal HSC that collaborates with oncogene-driven programs to confer aggressive behavior in HSC-AML. We find that components of this program are required for HSC-AML growth and survival and identify RNA polymerase (RNAP) II-mediated transcription as a therapeutic vulnerability. Overall, we propose a mechanism as to how epigenetic programs from the leukemic cell of origin are inherited through transformation to impart the clinical heterogeneity of AML.